Latest news with #Yuhan
Yahoo
19 hours ago
- Business
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
20 hours ago
- Business
- Yahoo
Asian Value Stocks Estimated Below Intrinsic Worth
As global markets navigate a complex landscape, the Asian financial scene is drawing attention with its potential for value investing, particularly as China's economic indicators suggest room for further stimulus and Japan's moderate recovery continues. In this environment, identifying stocks that are trading below their intrinsic worth can be an effective strategy, offering opportunities to capitalize on market inefficiencies while mitigating risk through thorough analysis. Name Current Price Fair Value (Est) Discount (Est) Wenzhou Yihua Connector (SZSE:002897) CN¥38.99 CN¥76.64 49.1% Taiyo Yuden (TSE:6976) ¥2411.50 ¥4741.52 49.1% Livero (TSE:9245) ¥1692.00 ¥3352.54 49.5% Kanto Denka Kogyo (TSE:4047) ¥841.00 ¥1677.13 49.9% Hangzhou Zhongtai Cryogenic Technology (SZSE:300435) CN¥16.67 CN¥33.21 49.8% Gushengtang Holdings (SEHK:2273) HK$38.35 HK$76.50 49.9% Fuji (TSE:6134) ¥2253.50 ¥4448.27 49.3% Everest Medicines (SEHK:1952) HK$54.55 HK$107.01 49% Brangista (TSE:6176) ¥597.00 ¥1180.86 49.4% Boditech Med (KOSDAQ:A206640) ₩15850.00 ₩31439.92 49.6% Click here to see the full list of 302 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Below we spotlight a couple of our favorites from our exclusive screener. Overview: Yuhan Corporation is a South Korean company that manufactures and sells prescription drugs, over-the-counter drugs, veterinary drugs, and household goods both domestically and internationally, with a market cap of ₩8.04 trillion. Operations: The company's revenue segments include biotechnology startups, which contribute ₩2.11 billion to its overall earnings. Estimated Discount To Fair Value: 22.4% Yuhan's current trading price of ₩107,300 is significantly below its estimated fair value of ₩138,269.28, suggesting it may be undervalued based on cash flows. Despite a forecasted 44% annual earnings growth outpacing the Korean market average, recent financials show declining profit margins and net income compared to the previous year. The company has engaged in substantial share buybacks over time but reported no repurchases in early 2025. Our comprehensive growth report raises the possibility that Yuhan is poised for substantial financial growth. Click here and access our complete balance sheet health report to understand the dynamics of Yuhan. Overview: ASMPT Limited is an investment holding company that designs, manufactures, and markets machines, tools, and materials for the semiconductor and electronics assembly industries globally, with a market cap of HK$23.74 billion. Operations: The company's revenue is primarily derived from its Semiconductor Solutions segment, which generated HK$7.42 billion, and its Surface Mount Technology (SMT) Solutions segment, contributing HK$5.79 billion. Estimated Discount To Fair Value: 41.9% ASMPT's current trading price of HK$57 is significantly below its estimated fair value of HK$98.04, highlighting potential undervaluation based on cash flows. Despite a decrease in profit margins and net income compared to the previous year, ASMPT anticipates revenue growth between US$410 million and US$470 million for Q2 2025, driven by seasonal factors and strong bookings. The company declared a special dividend of HKD 0.25 per share but reduced its final dividend to HKD 0.07 per share for 2024. The analysis detailed in our ASMPT growth report hints at robust future financial performance. Get an in-depth perspective on ASMPT's balance sheet by reading our health report here. Overview: Accton Technology Corporation is engaged in the research, development, manufacturing, and sale of network communication equipment across Taiwan, America, Asia, Europe, and other international markets with a market cap of NT$411.92 billion. Operations: The company's revenue primarily comes from its Computer Networks segment, which generated NT$134.33 billion. Estimated Discount To Fair Value: 33.9% Accton Technology's current trading price of NT$737 is substantially below its estimated fair value of NT$1115.68, suggesting undervaluation based on cash flows. The company reported significant earnings growth for Q1 2025, with net income rising to TWD 5.13 billion from TWD 2.24 billion a year earlier. Despite high non-cash earnings, Accton's projected revenue and profit growth rates exceed Taiwan's market averages, indicating robust future performance potential despite moderate annual profit growth forecasts. Our earnings growth report unveils the potential for significant increases in Accton Technology's future results. Click to explore a detailed breakdown of our findings in Accton Technology's balance sheet health report. Access the full spectrum of 302 Undervalued Asian Stocks Based On Cash Flows by clicking on this link. Got skin in the game with these stocks? Elevate how you manage them by using Simply Wall St's portfolio, where intuitive tools await to help optimize your investment outcomes. Elevate your portfolio with Simply Wall St, the ultimate app for investors seeking global market coverage. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:522 and TWSE:2345. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Globe and Mail
a day ago
- Health
- Globe and Mail
Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
"Obesity Drugs Market" Obesity Companies such as Yuhan, Click Therapeutics, Novo Nordisk, ProQR Therapeutics, Bukwang Pharmaceutical, Empros Pharma, Boehringer Ingelhium, Rhythm Pharmaceuticals, BioRestorative Therapies, Hanmi Pharmaceuticals, Carmot Therapeutics, D&D Pharmatech, SCOHIA PHARMA, Nano Precision Medical, Terns Pharmaceuticals, Caliway Biopharmaceutics, Eli Lilly and Company, and others (Albany, USA) DelveInsight's 'Obesity Market Insights, Epidemiology, and Market Forecast-2034' report delivers an in-depth understanding of Obesity, historical and forecasted epidemiology as well as the Obesity market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan. The Obesity market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Obesity market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Obesity treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Obesity market. Request for a Free Sample Report @ Obesity Market Forecast Some facts of the Obesity Market Report are: In March 2025, Novo Nordisk launched NovoCare® Pharmacy, a direct-to-patient delivery service, to ensure access to Wegovy® (semaglutide) injection in all dose strengths (0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg). This service offers uninsured patients or those with commercial insurance lacking obesity medicine coverage the option to purchase Wegovy® at a reduced cost of $499 per month. This initiative expands Novo Nordisk's efforts to meet the needs of individuals living with obesity, following the FDA's confirmation that the shortage of the medication has been resolved and that all doses now meet or exceed U.S. demand. In February 2025, Eli Lilly launched 7.5 mg and 10 mg Zepbound (tirzepatide) vials for $499 through the Zepbound Self Pay Journey Program, alongside price reductions for 2.5 mg and 5 mg vials. These are available exclusively via LillyDirect Self Pay Pharmacy Solutions, offering direct savings outside of insurance. In February 2025, Amgen announced that the U.S. FDA has placed a hold on a study of the company's early-stage obesity candidate, AMG 513, marking another potential setback in its efforts to enter the growing weight loss drug market. Amgen has provided limited information about the drug, including its mechanism of action. In January 2025, Novo Nordisk reported that a high dose of its obesity drug Wegovy led to greater weight loss than the approved regimen in a Phase III trial. However, the data also suggest that Eli Lilly's rival GLP-1 drug Zepbound may still have an advantage over Wegovy. In January 2025, Verdiva Bio Limited launched as a clinical-stage biopharmaceutical company focused on innovative therapies for obesity and cardiometabolic disorders. The company is advancing next-generation oral and injectable treatments and raised $411M in an oversubscribed Series A round, co-led by Forbion and General Atlantic, with participation from RA Capital Management, OrbiMed, Logos Capital, Lilly Asia Ventures, and LYFE Capital. In January 2025, Eli Lilly filed a motion to intervene as a defendant in a case between the Outsourcing Facilities Association and FarmaKeio Custom Compounding against the FDA. The court has ordered the Outsourcing Facilities Association to respond by January 15, with Eli Lilly's reply due by January 21. As per DelveInsight's estimates, the United States accounted for the highest number of total prevalent cases of Obesity among the 7MM in 2023. DelveInsight's consultant estimates that adult patients constituted the maximum number of cases of obesity patients seeking help in 2023. According to the findings, treatment rate for children was found to be less than that of adults across countries. Among EU4 and the UK, the highest number of treated cases of obesity in adults was observed in the United Kingdom in 2023, which is followed by Germany. The leading Obesity Companies such as Rhythm Pharmaceuticals, Boehringer Ingelhium, D&D Pharmatech, ProQR Therapeutics, Nano Precision Medical, Bukwang Pharmaceutical, Caliway Biopharmaceutics, Yuhan, Terns Pharmaceuticals, BioRestorative Therapies, SCOHIA PHARMA, Click Therapeutics, Hanmi Pharmaceuticals, Novo Nordisk, Empros Pharma, Carmot Therapeutics, Eli Lilly and Company, and others Promising Obesity Therapies such as IMCIVREE (setmelanotide), ZEPBOUND (tirzepatide), Semaglutide oral, Survodutide (BI 456906), DD03, AX-0601, NPM 139, BK-1701, CBW-520, YH34160, TERN-601, Thermostem, SCO-267, CT-181, HM15136, NNC0480-0389, EMP-16, CT-868, Semaglutide, and others. On June 2023, Eli Lilly and Company (NYSE: LLY) announced the new phase 2 data from retatrutide, Lilly's investigational molecule being studied for the treatment of obesity. At 24 weeks, retatrutide (1 mg, 4 mg, 8 mg or 12 mg) met the primary endpoint for the efficacy estimand in participants living with obesity or overweight without diabetes, demonstrating a mean weight reduction up to 17.5% (41.2 lb. or 18.7 kg). In a secondary endpoint, retatrutide demonstrated a mean weight reduction up to 24.2% (57.8 lb. or 26.2 kg)ii at the end of the 48-week treatment duration. On June 2023, Pfizer (NYSE: PFE) updated that it is scrapping its once-a-day experimental obesity pill because of concerns about liver safety, but will continue developing its other obesity pill, the twice-daily treatment danuglipron, as it races to rival the success of other weight loss treatments. On May 2023, Novo Nordisk (NYSE: NVO) announced positive results from a phase IIIa study, OASIS 1, in the global OASIS program for a once-daily oral formulation of semaglutide in obesity. Obesity Overview Obesity is a chronic condition characterized by an excessive accumulation of body fat, leading to adverse health effects and increased risk of various diseases. It is typically defined by a body mass index (BMI) of 30 or higher. Obesity results from complex interactions between genetic, environmental, socioeconomic, and behavioral factors. Sedentary lifestyles, high-calorie diets, and genetic predispositions contribute to its development. Obesity is associated with numerous health complications, including type 2 diabetes, cardiovascular disease, hypertension, certain cancers, and musculoskeletal disorders. Additionally, it can impair quality of life and increase mortality rates. Prevention and management strategies for obesity include dietary modifications, regular physical activity, behavioral therapy, medications, and in severe cases, bariatric surgery. Public health initiatives and policies aimed at promoting healthy lifestyles and reducing obesity prevalence are essential to address this global epidemic and its associated health burdens. Learn more about Obesity treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Obesity Market The Obesity market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Obesity market trends by analyzing the impact of current Obesity therapies on the market and unmet needs, and drivers, barriers, and demand for better technology. This segment gives a thorough detail of the Obesity market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Obesity market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to DelveInsight, the Obesity market in 7MM is expected to witness a major change in the study period 2020-2034. Obesity Epidemiology The Obesity epidemiology section provides insights into the historical and current Obesity patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Obesity market report also provides the diagnosed patient pool, trends, and assumptions. Explore more about Obesity Epidemiology @ Obesity Market Dynamics Obesity Drugs Uptake This section focuses on the uptake rate of the potential Obesity drugs recently launched in the Obesity market or expected to be launched in 2020-2034. The analysis covers the Obesity market uptake by drugs, patient uptake by therapies, and sales of each drug. Obesity Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Obesity market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Obesity Pipeline Development Activities The Obesity report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Obesity key players involved in developing targeted therapeutics. Request for a sample report to understand more about the Obesity pipeline development activities @ Obesity Medication and Approved drugs Obesity Therapeutics Assessment Major key companies are working proactively in the Obesity Therapeutics market to develop novel therapies which will drive the Obesity treatment markets in the upcoming years are Novo Nordisk, Eli Lilly and Company, MedImmune, Boehringer Ingelheim, Raziel Therapeutics, Altimmune, Saniona, YSOPIA Bioscience, Innovent Biologics, Glaceum, Shionogi, Aardvark Therapeutics, NuSirt Biopharma, Novartis, CSPC Baike (Shandong) Biopharmaceutical, Jiangsu HengRui Medicine, Carmot Therapeutics, Pfizer, Sciwind Biosciences, Empros Pharma and others. Learn more about the emerging Obesity therapies & key companies @ Obesity Clinical Trials and Advancements Obesity Report Key Insights 1. Obesity Patient Population 2. Obesity Market Size and Trends 3. Key Cross Competition in the Obesity Market 4. Obesity Market Dynamics (Key Drivers and Barriers) 5. Obesity Market Opportunities 6. Obesity Therapeutic Approaches 7. Obesity Pipeline Analysis 8. Obesity Current Treatment Practices/Algorithm 9. Impact of Emerging Therapies on the Obesity Market Table of Contents 1. Key Insights 2. Executive Summary 3. Obesity Competitive Intelligence Analysis 4. Obesity Market Overview at a Glance 5. Obesity Disease Background and Overview 6. Obesity Patient Journey 7. Obesity Epidemiology and Patient Population 8. Obesity Treatment Algorithm, Current Treatment, and Medical Practices 9. Obesity Unmet Needs 10. Key Endpoints of Obesity Treatment 11. Obesity Marketed Products 12. Obesity Emerging Therapies 13. Obesity Seven Major Market Analysis 14. Attribute Analysis 15. Obesity Market Outlook (7 major markets) 16. Obesity Access and Reimbursement Overview 17. KOL Views on the Obesity Market 18. Obesity Market Drivers 19. Obesity Market Barriers 20. Appendix 21. DelveInsight Capabilities 22. Disclaimer About DelveInsight DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector. Media Contact Company Name:DelveInsight Business Research LLP Contact Person: Ankit Nigam Email:Send Email Phone: +14699457679 Address:304 S. Jones Blvd #2432 City: Albany State: New York Country: United States Website: Press Release Distributed by To view the original version on ABNewswire visit: Obesity Drugs Market 2034: Clinical trials, EMA, PDMA, FDA Approvals, Medication, Statistics, Revenue, Therapies, Prevalence and Companies by DelveInsight
News18
28-04-2025
- Automotive
- News18
Rs 1.8 Crore Mercedes Maybach As Taxi? Chinese Driver's Choice Is Being Applauded
Based in Beijing, Yuan invested 1.55 million yuan (about Rs 1.8 crore) in the ultra-luxury car for his ride-hailing service, which he's run since 2019. Indian commuters are used to seeing Maruti Suzuki or Hyundai cars as their go-to cab options. These vehicles dominate the ride-hailing scene thanks to their fuel efficiency and low maintenance costs. However, things look quite different in other countries like China or the United States. Recently, a cab driver in China made headlines for his rather extravagant choice of wheels — a Mercedes-Maybach S480, valued at nearly Rs 2 crore. According to the South China Morning Post, the driver, identified only by his surname Yuan, is based in Beijing and reportedly invested 1.55 million yuan (approximately Rs 1.80 crore) in the ultra-luxurious sedan for his taxi service. He has been in the ride-hailing business since 2019 and claims to be earning more than Rs 58,000 in just one trip. He shares glimpses of his unique journey on his social media handle titled 'Old Yuan Drives a Maybach for Ride-Hailing" and has over 120,000 followers online. In a video posted earlier this month, Yuan shared a fascinating experience. He revealed that one day, he started working at 6:45 AM and secured a full-day trip, for which he charged 4,000 yuan (approximately Rs. 46,000). 'Let's go! Driving a luxury Maybach ride-hailing car is not only my job but also my livelihood. Currently, the Maybach model can only be specifically ordered for ride-hailing in Beijing and Shanghai. It is uncertain when it will be available in other cities, so please watch rationally," Yuan said in the clip, as quoted by the SCMP. In an interview with Haibao News, the driver opened up about how he manages the expenses of maintaining a high-end car like the Mercedes-Maybach S480. He completes almost 40 rides every month and, for each trip, earns more than 5,000 yuan (about Rs. 58,600). Keeping aside all the costs, he manages to save 10,000 yuan ( Rs. 1.1 lakh), which is enough for his relaxed lifestyle. 'My monthly fuel costs are about 3,000 yuan (Rs. 35,000). I spend another 2,000 to 3,000 yuan (Rs. 23,000 to Rs. 35,000) on food, and rent is 4,500 yuan (Rs. 52,700). I still have some savings left. The best part is that I get to drive a Maybach at only 30," Yuhan said, as per the SCMP report. Yuan purchased the car on EMI, making a downpayment of 680,000 yuan (Rs. 79.7 lakh). Most of the money came from his savings of over six years. For the remaining amount, he needs to pay a monthly instalment of 14,466 yuan (Rs. 1.7 lakh) for five years.
Yahoo
16-03-2025
- Business
- Yahoo
Asian Stocks That May Be Trading Below Their Estimated Value In March 2025
As global markets grapple with inflation concerns and trade uncertainties, Asian economies are navigating a complex landscape marked by modest gains in Japan's stock markets and stimulus hopes in China. In this environment, identifying stocks that may be trading below their estimated value can present opportunities for investors seeking to capitalize on potential market inefficiencies. Name Current Price Fair Value (Est) Discount (Est) Zhejiang Cfmoto PowerLtd (SHSE:603129) CN¥178.81 CN¥351.04 49.1% Insource (TSE:6200) ¥804.00 ¥1584.36 49.3% Guangdong Fenghua Advanced Technology (Holding) (SZSE:000636) CN¥15.40 CN¥30.37 49.3% APAC Realty (SGX:CLN) SGD0.42 SGD0.83 49.7% JSHLtd (TSE:150A) ¥561.00 ¥1107.45 49.3% GMO internet group (TSE:9449) ¥3149.00 ¥6181.69 49.1% Nanofilm Technologies International (SGX:MZH) SGD0.665 SGD1.33 49.9% BalnibarbiLtd (TSE:3418) ¥1092.00 ¥2179.32 49.9% Jiangsu Chuanzhiboke Education Technology (SZSE:003032) CN¥8.54 CN¥16.97 49.7% Doosan Fuel Cell (KOSE:A336260) ₩15910.00 ₩31537.45 49.6% Click here to see the full list of 276 stocks from our Undervalued Asian Stocks Based On Cash Flows screener. Underneath we present a selection of stocks filtered out by our screen. Overview: Yuhan Corporation manufactures and sells prescription, over-the-counter, and veterinary drugs as well as household goods in South Korea and internationally, with a market cap of ₩9.34 trillion. Operations: The company's revenue segments include prescription drugs, over-the-counter drugs, veterinary drugs, and household goods. Estimated Discount To Fair Value: 41.3% Yuhan Corporation is trading at ₩124,800, significantly below its estimated fair value of ₩212,677.73, presenting an undervaluation opportunity based on cash flows. Despite a decline in net income to KRW 70.69 billion for 2024 from KRW 136.20 billion the previous year and reduced profit margins of 3.4%, earnings are projected to grow at a robust rate of over 35% annually, outpacing the market's growth expectations and indicating potential for future profitability improvements. Our expertly prepared growth report on Yuhan implies its future financial outlook may be stronger than recent results. Take a closer look at Yuhan's balance sheet health here in our report. Overview: Swire Properties Limited, with a market cap of HK$99.11 billion, develops, owns, and operates mixed-use commercial properties in Hong Kong, Mainland China, the United States, and internationally through its subsidiaries. Operations: The company's revenue segments include Property Investment at HK$14.77 billion, Hotels at HK$854 million, and Property Trading at HK$81 million. Estimated Discount To Fair Value: 43% Swire Properties is trading at HK$17.14, significantly below its estimated fair value of HK$30.09, highlighting an undervaluation based on cash flows. Despite a net loss of HK$766 million for 2024 and dividends not being well-covered by earnings or free cash flows, earnings are forecast to grow 35% annually with expected profitability in three years. This growth rate surpasses the Hong Kong market's average revenue growth expectation and suggests potential for future value realization. According our earnings growth report, there's an indication that Swire Properties might be ready to expand. Unlock comprehensive insights into our analysis of Swire Properties stock in this financial health report. Overview: Giant Biogene Holding Co., Ltd. is an investment holding company focused on the research, development, manufacture, and sale of bioactive material-based beauty and health products in China, with a market cap of HK$72.05 billion. Operations: The company generates revenue from its biotechnology segment, amounting to CN¥4.46 billion. Estimated Discount To Fair Value: 27.8% Giant Biogene Holding, trading at HK$70.85, is undervalued based on cash flows with a fair value estimate of HK$98.08. The stock trades 27.8% below this estimate and earnings are expected to grow significantly over the next three years at 23.87% annually, outpacing the Hong Kong market's average growth rate of 11.6%. Revenue is forecast to grow at 19.6% per year, further supporting its potential for value realization despite slower than ideal revenue growth rates. Upon reviewing our latest growth report, Giant Biogene Holding's projected financial performance appears quite optimistic. Click to explore a detailed breakdown of our findings in Giant Biogene Holding's balance sheet health report. Get an in-depth perspective on all 276 Undervalued Asian Stocks Based On Cash Flows by using our screener here. Have you diversified into these companies? Leverage the power of Simply Wall St's portfolio to keep a close eye on market movements affecting your investments. Streamline your investment strategy with Simply Wall St's app for free and benefit from extensive research on stocks across all corners of the world. Explore high-performing small cap companies that haven't yet garnered significant analyst attention. Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence. Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include KOSE:A000100 SEHK:1972 and SEHK:2367. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
